Optimizing weight control in diabetes: antidiabetic drug selection

S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, san...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Kalra S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	weight control diabetes antidiabetic drugs Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/f156546818cd4b9fb6e2e02aca6296a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f156546818cd4b9fb6e2e02aca6296a7
record_format	dspace
spelling	oai:doaj.org-article:f156546818cd4b9fb6e2e02aca6296a72021-12-02T01:30:18ZOptimizing weight control in diabetes: antidiabetic drug selection1178-7007https://doaj.org/article/f156546818cd4b9fb6e2e02aca6296a72010-08-01T00:00:00Zhttps://www.dovepress.com/optimizing-weight-control-in-diabetes-antidiabetic-drug-selection-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, BMS, and AstraZeneca.Clinical question: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control.Implementation: • Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.• Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.Keywords: weight control, diabetesKalra SDove Medical Pressarticleweight controldiabetesantidiabetic drugsSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 297-299 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	weight control diabetes antidiabetic drugs Specialties of internal medicine RC581-951
spellingShingle	weight control diabetes antidiabetic drugs Specialties of internal medicine RC581-951 Kalra S Optimizing weight control in diabetes: antidiabetic drug selection
description	S Kalra1, B Kalra1, AG Unnikrishnan2, N Agrawal3, S Kumar41Bharti Hospital, Karnal; 2Amrita Institute of Medical Science, Kochi; 3Medical College, Gwalior; 4Excel Life Sciences, Noida, IndiaDate of preparation: 18th August 2010Conflict of interest: SK has received speaker fees from Novo Nordisk, sanofi-aventis, MSD, Eli Lilly, BMS, and AstraZeneca.Clinical question: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes?Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control.Implementation: • Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.• Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.Keywords: weight control, diabetes
format	article
author	Kalra S
author_facet	Kalra S
author_sort	Kalra S
title	Optimizing weight control in diabetes: antidiabetic drug selection
title_short	Optimizing weight control in diabetes: antidiabetic drug selection
title_full	Optimizing weight control in diabetes: antidiabetic drug selection
title_fullStr	Optimizing weight control in diabetes: antidiabetic drug selection
title_full_unstemmed	Optimizing weight control in diabetes: antidiabetic drug selection
title_sort	optimizing weight control in diabetes: antidiabetic drug selection
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/f156546818cd4b9fb6e2e02aca6296a7
work_keys_str_mv	AT kalras optimizingweightcontrolindiabetesantidiabeticdrugselection
_version_	1718403050615341056

Optimizing weight control in diabetes: antidiabetic drug selection

Ejemplares similares